Beltrán Luis M, Rubio-Navarro Alfonso, Amaro-Villalobos Juan Manuel, Egido Jesús, García-Puig Juan, Moreno Juan Antonio
Metabolic-Vascular Unit, Fundación IdiPAZ-Hospital Universitario La Paz, Madrid, Spain.
Vascular, Renal, and Diabetes Research Lab, IIS-Fundación Jiménez Díaz, Madrid, Spain.
Vasc Health Risk Manag. 2015 Jan 6;11:35-48. doi: 10.2147/VHRM.S65885. eCollection 2015.
Patients infected with the human immunodeficiency virus (HIV) have an increased cardiovascular risk. Although initially this increased risk was attributed to metabolic alterations associated with antiretroviral treatment, in recent years, the attention has been focused on the HIV disease itself. Inflammation, immune system activation, and endothelial dysfunction facilitated by HIV infection have been identified as key factors in the development and progression of atherosclerosis. In this review, we describe the epidemiology and pathogenesis of cardiovascular disease in patients with HIV infection and summarize the latest knowledge on the relationship between traditional and novel inflammatory, immune activation, and endothelial dysfunction biomarkers on the cardiovascular risk associated with HIV infection.
感染人类免疫缺陷病毒(HIV)的患者心血管风险增加。尽管最初这种风险增加归因于与抗逆转录病毒治疗相关的代谢改变,但近年来,注意力已集中在HIV疾病本身。HIV感染所促成的炎症、免疫系统激活和内皮功能障碍已被确定为动脉粥样硬化发生和发展的关键因素。在本综述中,我们描述了HIV感染患者心血管疾病的流行病学和发病机制,并总结了关于传统和新型炎症、免疫激活及内皮功能障碍生物标志物与HIV感染相关心血管风险之间关系的最新知识。